Organization · Venture Studio
AION Labs
AION Labs is a venture studio that connects pharmaceutical R&D with advancements in AI and technology to accelerate drug discovery and development. It collaborates with major pharmaceutical companies to address unmet needs in the industry.
Overview
What AION Labs does
What AION Labs is
AION Labs is a venture studio that connects pharmaceutical R&D with advancements in AI and technology to accelerate drug discovery and development. It collaborates with major pharmaceutical companies to address unmet needs in the industry.
How it participates in the startup ecosystem
The current public profile supports funder and program host and event host and publisher capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Studio
- Founded
- Founded in 2021
- Approximate age
- About 5 years
- Structured capabilities
- Funder · Program host · Event host · Publisher
- Last reviewed
- March 27, 2026
What Venture studio means
A venture studio is an organization that systematically creates new startups by generating or sourcing ideas, validating them, building early products, recruiting founders or operators, providing shared resources, and retaining meaningful equity in the companies it helps create.
Open the glossary entryOfficial channels
Find AION Labs elsewhere
Open the official website or a supported primary organization account.
Capability profile
AION Labs as a funder
Investment thesis
AION Labs focuses on connecting pharmaceutical R&D with advancements in AI and technology to accelerate drug discovery and development.
Focus narrative
AION Labs invests in AI-driven solutions specifically targeting unmet needs in the pharmaceutical industry, particularly in drug discovery and development. The organization operates through two main tracks: AION Building, which addresses predefined challenges from pharmaceutical partners, and AION Seeding, which supports early-stage startups and technologies transitioning from academia.
Value beyond capital
AION Labs provides value to its portfolio companies through collaboration with pharmaceutical partners, ensuring industry alignment, reducing risks, and offering validation and funding for early-stage technologies.
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A
- Sectors
- Biotech · AI · Healthcare · Health Data
- Regions
- Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 7
- Recorded notable exits
- Combinable
Portfolio context
Notable companies in AION Labs' portfolio include Renasis Bio, an AI-driven platform for RNA-targeting drug discovery; Cassidy Bio, focused on genome editing therapeutics; Cellyrix, pioneering cancer treatment using AI; Combinable, which developed an in silico solution for antibody optimization; Denovai, an AI platform for dynamic protein design; Promise Bio, specializing in epiproteomic analysis; and ProPhet, which identifies active small molecules for drug discovery using machine learning.
Capability profile
AION Labs as a program host
Program thesis
AION Labs is a venture studio focused on connecting pharmaceutical research and development (R&D) with advancements in artificial intelligence (AI), technology, and scientific innovation.
Focus narrative
AION Labs invests in AI-driven solutions for the pharmaceutical industry, specifically targeting unmet needs in drug discovery and development. The organization operates through two main tracks: AION Building, which focuses on predefined challenges set by pharmaceutical partners, and AION Seeding, which supports early-stage startups and technologies transitioning from academia.
Value and support
AION Labs offers a collaborative venture studio model that emphasizes partnerships with pharmaceutical companies, providing validation, funding, and support for early-stage startups and technologies.
Availability
- Application state
- Not published
Focus and fit
- Stages
- Pre-seed · Seed
- Regions
- Global
Alumni and track record
Alumni context
Notable companies within AION Labs' portfolio include Renasis Bio, an AI-driven platform for RNA-targeting drug discovery; Cassidy Bio, focused on advancing genome editing therapeutics; Cellyrix, pioneering cancer treatment using AI; Combinable, which developed an in silico solution for antibody optimization; Denovai, an AI-based platform for dynamic protein design; Promise Bio, for unbiased epiproteomic analysis; and ProPhet, which utilizes machine learning for drug discovery.
Capability profile
AION Labs as an event host
Event focus
AION Labs invests in AI-driven solutions for the pharmaceutical industry, specifically targeting unmet needs in drug discovery and development. The organization operates through two main tracks: AION Building, which focuses on predefined challenges set by pharmaceutical partners, and AION Seeding, which supports early-stage startups and technologies transitioning from academia. The venture studio model emphasizes collaboration with pharmaceutical companies to ensure industry alignment and reduce risks.
Format narrative
AION Labs operates through two main company creation tracks: AION Building for predefined challenges and AION Seeding for early-stage startups.
Participant value
AION Labs aims to accelerate the creation, validation, and scaling of solutions that transform drug discovery and development by connecting pharmaceutical R&D with advancements in AI and technology.
Format and cadence
- Startups can present
- No
Availability
- Registration state
- Not currently accepting
Audience and fit
- Stages
- Pre-seed · Seed
- Audience
- Founders · Investors
- Regions
- Global
Capability profile
AION Labs as a publisher
Editorial focus
AION Labs is a venture studio dedicated to bridging the gap between pharmaceutical research and development and advancements in artificial intelligence and technology. The organization focuses on investing in AI-driven solutions that address unmet needs in drug discovery and development, operating through two main tracks: AION Building and AION Seeding. This model emphasizes collaboration with pharmaceutical companies to ensure industry alignment and mitigate risks.
Audience value
AION Labs accelerates the creation, validation, and scaling of innovative solutions in drug discovery and development, leveraging AI and collaboration with pharmaceutical partners to transform the industry.
Format and cadence
- Content formats
- podcast
- Primary platform
- Spotify
Availability
- Guest pitch state
- Not currently accepting
Audience and focus
- Audience
- Founders · Researchers
- Regions
- Global
Flagship work and coverage
Flagship properties
AION Labs produces podcasts such as 'About Medicines, Innovation and the Future of Biotech' and '8200Bio BioNation Podcast', featuring insights from the CEO.
Common questions
What to know about AION Labs
Upseed classifies AION Labs under the Venture Studio organization type. Its current public profile includes funder, program host, event host, and publisher capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 27, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.